Developing drugs that target novel biological pathways

Products to enhance manufacturing efficiency and economics

Highlights

• June 9, 2010: Repligen Reports Fourth Quarter and Fiscal Year 2010 Financial Results More
• May 27, 2010: Repligen Announces FDA and EMA Approval of Re-analysis of Images from Phase 3 Trial of RG1068 for Pancreatic Imaging More
• May 24, 2010: Repligen Receives Orphan Drug Designation for RG2833 for Friedreich's ataxia More
• View All